Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Dexamethasone × Dermatologic × Clear all

Phase

Phase 2 4 Phase 1 3 Phase NA 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 102 Lymphoid 35 Other hematologic neoplasm 28 Genitourinary 6 Gastrointestinal 6 Thoracic 5 Myeloid 3 Gynecologic 3 CNS 3 Breast 3 Tumor-Agnostic 2 Head & Neck 2 Other solid neoplasm 1 NET 1 Endocrine 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 65 Nivolumab 48 Ipilimumab 36 Cyclophosphamide 33 aldesleukin 25 Interleukin-2 20 fludarabine 16 fludarabine phosphate 15 Temozolomide 15 trametinib 10 dabrafenib 10 Radiotherapy 10 Biopsy 10 avelumab 8 Bevacizumab 8 sargramostim 7 cemiplimab 7 Paclitaxel 7 Cisplatin 7 lenvatinib 6 Magnetic Resonance Spectroscopy 6 Fluorouracil 6 Dacarbazine 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 Specimen Handling 5 Peripheral Blood Stem Cell Transplantation 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 epacadostat 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡